Sagent Pharmaceuticals, Inc. Announces the Launch of Caffeine Citrate Injection, USP and Caffeine Citrate Oral Solution, USP

SCHAUMBURG, Ill., Oct. 3, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Caffeine Citrate Injection, USP and Caffeine Citrate Oral Solution, USP, central nervous system stimulants, in two latex-free vial presentations. According to IMS, for the 12 months ending July 2012, the US market for Caffeine Citrate Injection, USP and Caffeine Citrate Oral Solution, USP approximated $28.5 million. As with all products in Sagent's portfolio, Caffeine features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.